Enrolling By Invitation INTERVENTIONAL NCT04194216

Antibiotic Prophylaxis in Rhinoplasty

Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics

Sponsor: Duke University

Conditions Nasal Obstruction Nasal Surgical Procedures

Interventions Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

Updated 11 times since 2020 Last updated: Apr 21, 2026 Started: May 20, 2020 Primary completion: Dec 20, 2026 Completion: Apr 20, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Nasal Obstruction and Nasal Surgical Procedures and is currently ongoing. Duke University leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

The study will consist of 2 treatment arms: Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.

The study will consist of 2 treatment arms:

Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.

Status Flow

Change History

11 versions recorded

Apr 28, 2026 — Present [daily]

Enrolling By Invitation

Phase: PHASE3 → None
Jan 2025 — Apr 2026 [monthly]

Enrolling By Invitation PHASE3
Sep 2024 — Jan 2025 [monthly]

Enrolling By Invitation PHASE3
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE3
Jan 2024 — Jul 2024 [monthly]

Enrolling By Invitation PHASE3

▶ Show 6 earlier versions

Nov 2022 — Jan 2024 [monthly]

Enrolling By Invitation PHASE3
Oct 2021 — Nov 2022 [monthly]

Enrolling By Invitation PHASE3
Jan 2021 — Oct 2021 [monthly]

Enrolling By Invitation PHASE3
Aug 2020 — Jan 2021 [monthly]

Enrolling By Invitation PHASE3

Status: Not Yet Recruiting → Enrolling By Invitation
Mar 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE3
Jan 2020 — Mar 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Contact Information

Sponsor contact:

Duke University
Harvard University
Loma Linda University
Stanford University
University of Cincinnati
University of Kansas Medical Center
University of Washington
Vanderbilt University School of Medicine
Washington University School of Medicine

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States